Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catalyst Pharm Inc (CPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Free Research Reports on Catalent and Three More Generic Drugs Stocks

Stock Research Monitor: CPRX, COLL, and DPLO

COLL : 18.89 (-2.63%)
CTLT : 42.98 (+0.28%)
CPRX : 3.17 (-1.86%)
Innovative Biotech Companies, Preparing for the Future

LAS VEGAS, NV / ACCESSWIRE / June 15, 2018 / Some innovative biotechnology companies that are working on ground-breaking technology and are prepared for the future include: Propanc Biopharma, Inc. (OTCQB:...

CLDX : 0.51 (unch)
PPCHD : 1.2000 (+20.00%)
AQXP : 2.83 (+11.86%)
PPCB : 0.0330 (+3.13%)
CPRX : 3.17 (-1.86%)
Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 3.17 (-1.86%)
Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors

Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive...

CUR : 1.21 (unch)
OPNT : 15.60 (-0.89%)
CPRX : 3.17 (-1.86%)
Catalyst's Fridapse Gets Priority Review by FDA, Shares Up

The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.

LGND : 220.20 (+0.17%)
ILMN : 303.93 (+0.64%)
BMRN : 103.46 (+0.71%)
CPRX : 3.17 (-1.86%)
Catalyst Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 3.17 (-1.86%)
Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses

Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.

LGND : 220.20 (+0.17%)
CATB : 0.81 (-1.22%)
ENTA : 120.78 (-0.20%)
CPRX : 3.17 (-1.86%)
Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and Provides Corporate Update

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...

CPRX : 3.17 (-1.86%)
What's in Store for Catalyst (CPRX) This Earnings Season?

Catalyst (CPRX) is expected to report first-quarter 2018 results on May 9, after the market closesa and investor's focus will be on pipeline and regulatory updates during the earnings call.

CELG : 85.97 (+0.87%)
ADVM : 5.20 (unch)
EBS : 53.93 (+0.04%)
CPRX : 3.17 (-1.86%)
Catalyst Pharmaceuticals to Hold First Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, May 10th, 2018

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 3.17 (-1.86%)
Catalyst Pharmaceuticals Introduces New Corporate Website

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 3.17 (-1.86%)
Catalyst Enrolls First Patient in Phase III Firdapse Study

Catalyst (CPRX) enrolls the first patient in its phase III clinical trial (MSK-002) to evaluate the efficacy and safety of Firdapse in patients with MuSK antibody positive Myasthenia Gravis.

PTGX : 7.74 (+2.79%)
LGND : 220.20 (+0.17%)
BMRN : 103.46 (+0.71%)
CPRX : 3.17 (-1.86%)
Report: Developing Opportunities within Clean Energy Fuels, Catalyst Pharmaceuticals, Qorvo, Brunswick, DCT Industrial Trust, and Radius Health -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clean Energy Fuels Corp. (NASDAQ:CLNE),...

BC : 67.58 (-0.31%)
DCT : 65.62 (-0.95%)
RDUS : 28.52 (-0.77%)
CPRX : 3.17 (-1.86%)
QRVO : 81.96 (+0.77%)
CLNE : 2.71 (+2.65%)
Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse(R) in MuSK Antibody Positive Myasthenia Gravis

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 3.17 (-1.86%)
Catalyst Pharmaceuticals (CPRX) Down 7.4% Since Earnings Report: Can It Rebound?

Catalyst Pharmaceuticals (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CPRX : 3.17 (-1.86%)
Catalyst (CPRX) Up on New Drug Application for Firdapse

Catalyst (CPRX) new drug application for its lead pipeline candidate keeps it on a growth trajectory.

LGND : 220.20 (+0.17%)
BMRN : 103.46 (+0.71%)
REGN : 363.41 (-0.37%)
CPRX : 3.17 (-1.86%)
Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse(R) for Treatment of Lambert-Eaton Myasthenic Syndrome

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...

CPRX : 3.17 (-1.86%)
Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Allergan, Catalyst Pharma, Flexion Therapeutics, and Supernus Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on AGN, CPRX, FLXN, and SUPN which can be accessed for free by signing up to www.wallstequities.com/registration....

SUPN : 52.45 (-0.47%)
AGN : 175.02 (-0.36%)
CPRX : 3.17 (-1.86%)
FLXN : 27.22 (+0.93%)
Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress

Catalyst Pharma (CPRX) reports in-line fourth-quarter 2017 loss and is on track to resubmit its new drug application for Firdapse in the first quarter of 2018.

LGND : 220.20 (+0.17%)
ENTA : 120.78 (-0.20%)
REGN : 363.41 (-0.37%)
CPRX : 3.17 (-1.86%)
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update

--Firdapse NDA to be Resubmitted Before the End of this Quarter

CPRX : 3.17 (-1.86%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -0.36 , FTNT +0.55 , CAKE -0.12 , PLT -0.20 , AEO +0.35
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures are currently 3 to 4 cents higher after posting fractional to 2 cent gains in most contracts to start the week. Preliminary open interest was down 3,350 contracts yesterday, suggesting short covering. The USDA Export Inspections report s...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar